eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis
To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. O...
Saved in:
Published in | Inflammatory bowel diseases Vol. 20; no. 12; pp. 2276 - 2285 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Oxford University Press
01.12.2014
|
Subjects | |
Online Access | Get full text |
ISSN | 1078-0998 1536-4844 1536-4844 |
DOI | 10.1097/MIB.0000000000000199 |
Cover
Abstract | To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.ResultsA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.ConclusionsWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients. |
---|---|
AbstractList | BackgroundTo individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.ResultsA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.ConclusionsWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients. To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1. A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12. Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients. Background: To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Methods: Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constantcare.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI [< or =]1; FC = 0, and TIBS [< or =]1. Results: A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values ([< or =]1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12. Conclusions: Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients. To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.BACKGROUNDTo individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.METHODSProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.RESULTSA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.CONCLUSIONSWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients. To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.ResultsA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.ConclusionsWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients. |
Author | Martinsen, Lars Thielsen, Peter Duricova, Dana Bennedsen, Mette Jess, Tine Burisch, Johan Haaber, Anne Munkholm, Pia Pedersen, Natalia Bell, Sally Langholz, Ebbe Végh, Zsuzsanna |
Author_xml | – sequence: 1 givenname: Natalia surname: Pedersen fullname: Pedersen, Natalia organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark – sequence: 2 givenname: Peter surname: Thielsen fullname: Thielsen, Peter organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark – sequence: 3 givenname: Lars surname: Martinsen fullname: Martinsen, Lars organization: †Department of Gastroenterology, Nykoebing Falster Hospital, Nykoebing Falster, Denmark – sequence: 4 givenname: Mette surname: Bennedsen fullname: Bennedsen, Mette organization: ‡Department of Gastroenterology, Nordsjaellands Hospital, Frederikssund, Denmark – sequence: 5 givenname: Anne surname: Haaber fullname: Haaber, Anne organization: §Department of Gastroenterology, Gentofte Hospital, Gentofte, Denmark – sequence: 6 givenname: Ebbe surname: Langholz fullname: Langholz, Ebbe organization: §Department of Gastroenterology, Gentofte Hospital, Gentofte, Denmark – sequence: 7 givenname: Zsuzsanna surname: Végh fullname: Végh, Zsuzsanna organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark – sequence: 8 givenname: Dana surname: Duricova fullname: Duricova, Dana organization: ‖IBD Clinical and Research Center, ISCARE a. s., Charles University, Prague, Czech Republic – sequence: 9 givenname: Tine surname: Jess fullname: Jess, Tine organization: ¶Department of Epidemiology Research, States Serum Institute, Copenhagen, Denmark – sequence: 10 givenname: Sally surname: Bell fullname: Bell, Sally organization: Department of Gastroenterology, St. Vincent's University Hospital, Melbourne, Australia – sequence: 11 givenname: Johan surname: Burisch fullname: Burisch, Johan organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark – sequence: 12 givenname: Pia surname: Munkholm fullname: Munkholm, Pia organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25248002$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1q3DAUhU1IyV_zBqEIuunGiSRLlpVdO7TNQIYuMqFLoZGvMgqyNLXkQLPti1fJJFBm01wt7hF858DlHFf7IQaoqjOCzwmW4mIx_3KO_x0i5V51RHjT1qxjbL9oLLoaS9kdVscp3WNMy5MH1SHllHXle1T9gSvQPq8v0Tz07sH1k_buUWcXA4oWLSBprx9dALQcQecBQkbL9RinuzXS6Aa8rQcd9B306Ces6pVORd1EPz0nuIAWzvd1jvUQexh1BnTrzZNwD4Bm0bvs0vvqndU-wenLPqluv31dzq7q6x_f57PP17VhuMu1gE62DeFAOsGZ1EJYSgW3puWUWGkp76DphTWCECOtMaseSy6p0dS2DSfNSfVpm7sZ468JUlaDSwa81wHilBRpO8x4Kxv5BpTyhjHCcEE_7qD3cRpDOUQ1pJVCSklpoT68UNNqgF5tRjfo8bd6baIAl1vAjDGlEawyLj_3kEftvCJYPdWuSu1qt_ZiZjvm1_z_2C62tjht3ub4C375u4w |
CitedBy_id | crossref_primary_10_1007_s10620_018_5054_z crossref_primary_10_1097_MOG_0000000000000647 crossref_primary_10_1080_00365521_2020_1735506 crossref_primary_10_1080_14712598_2021_1942833 crossref_primary_10_3390_jcm9092905 crossref_primary_10_1093_ecco_jcc_jjw059 crossref_primary_10_1007_s10620_015_3620_1 crossref_primary_10_1016_j_cgh_2016_09_011 crossref_primary_10_1097_MIB_0000000000001082 crossref_primary_10_5217_ir_2017_15_4_434 crossref_primary_10_1016_j_cct_2015_03_006 crossref_primary_10_1186_s13075_022_02809_7 crossref_primary_10_1097_MIB_0000000000001034 crossref_primary_10_1080_00365521_2021_1892176 crossref_primary_10_26442_00403660_2018_12_000001 crossref_primary_10_1007_s11901_018_0412_z crossref_primary_10_1016_j_eii_2016_04_002 crossref_primary_10_1016_j_cgh_2015_10_035 crossref_primary_10_1111_jgh_13691 crossref_primary_10_1080_00365521_2022_2041083 crossref_primary_10_3748_wjg_v29_i7_1139 crossref_primary_10_1002_nur_22091 crossref_primary_10_12968_gasn_2022_20_6_30 crossref_primary_10_3748_wjg_v25_i40_6158 crossref_primary_10_2147_PPA_S383304 crossref_primary_10_3109_00365521_2015_1014407 crossref_primary_10_2147_PPA_S424024 crossref_primary_10_1080_00365521_2021_1966832 crossref_primary_10_1097_MIB_0000000000001026 crossref_primary_10_1177_20552076241261906 crossref_primary_10_1097_MPG_0000000000003053 crossref_primary_10_1038_s41598_023_46892_5 crossref_primary_10_1080_1744666X_2023_2292768 crossref_primary_10_1016_j_eii_2015_02_005 crossref_primary_10_2196_11761 crossref_primary_10_1002_hsr2_70186 crossref_primary_10_1016_j_imu_2022_100867 crossref_primary_10_1093_ecco_jcc_jjx169 crossref_primary_10_1111_imj_13677 crossref_primary_10_1016_j_cgh_2020_04_038 crossref_primary_10_2196_11602 crossref_primary_10_2196_14630 crossref_primary_10_1111_imj_15132 crossref_primary_10_1053_j_gastro_2022_01_024 crossref_primary_10_1186_s12913_022_08787_5 crossref_primary_10_1016_j_dld_2017_08_026 crossref_primary_10_1177_1357633X19849280 crossref_primary_10_1016_j_gastrohep_2024_502320 crossref_primary_10_2196_30291 crossref_primary_10_1186_s41687_021_00323_z crossref_primary_10_3390_genes12101465 crossref_primary_10_5056_jnm15071 crossref_primary_10_1093_ibd_izy162 crossref_primary_10_1016_j_ijmedinf_2023_105249 crossref_primary_10_1080_17474124_2017_1256200 crossref_primary_10_2196_31102 crossref_primary_10_3390_jpm15040123 crossref_primary_10_1093_ecco_jcc_jjae093 crossref_primary_10_3748_wjg_v23_i18_3356 crossref_primary_10_5217_ir_2018_16_3_366 crossref_primary_10_1016_S0140_6736_17_31327_2 crossref_primary_10_1038_s41598_023_35332_z crossref_primary_10_1093_ecco_jcc_jjy140 crossref_primary_10_5662_wjm_v13_i4_194 crossref_primary_10_1093_crocol_otaa002 crossref_primary_10_1097_MIB_0000000000000472 crossref_primary_10_1016_j_pec_2021_10_017 crossref_primary_10_1080_14712598_2019_1666101 crossref_primary_10_1080_00365521_2021_2015801 crossref_primary_10_1080_17474124_2016_1200464 crossref_primary_10_1111_jgh_14872 crossref_primary_10_17235_reed_2017_5143_2017 crossref_primary_10_1097_MIB_0000000000000676 |
Cites_doi | 10.1016/j.crohns.2011.09.008 10.1002/ibd.21841 10.1111/j.1365-2036.2012.05107.x 10.1136/gut.2010.220160 10.1016/j.crohns.2007.11.002 10.1016/j.cgh.2006.10.025 10.1046/j.1365-2036.2003.01648.x 10.1136/gut.43.1.29 10.1002/ibd.22895 10.1053/j.gastro.2006.10.011 10.1111/j.1572-0241.2007.01212.x 10.1111/j.1365-2036.2009.04164.x 10.3748/wjg.v20.i2.509 10.1080/00365520310000654 10.1002/ibd.20189 10.4088/PCC.v09n0202 10.1016/S0895-4356(98)00108-5 10.1038/ajg.2012.419 10.1038/ajg.2011.58 10.1016/j.cgh.2009.04.004 10.1111/j.1365-2036.2009.04103.x 10.1038/ajg.2011.67 10.1186/1743-422X-10-43 10.1136/gut.2004.056358 10.1136/gut.2004.060103 10.1038/ajg.2011.296 10.1371/journal.pone.0080633 10.1111/j.1547-5069.2006.00116.x 10.1002/ibd.20986 10.1111/j.1365-2036.2006.02809.x 10.3109/00365529609004876 10.1111/apt.12043 10.1002/ibd.22917 10.1002/ibd.20580 10.1586/17474124.2.3.299 10.1097/MEG.0b013e32833944bf 10.1111/j.1572-0241.2003.07522.x 10.1016/j.crohns.2011.11.002 10.1111/j.1365-2036.2010.04575.x 10.1002/ibd.21570 10.1007/s10620-011-1877-6 10.1016/j.crohns.2014.01.028 10.1111/apt.12650 10.1111/j.1365-2036.2008.03865.x 10.1097/01.MIB.0000436277.13917.c4 10.1016/j.crohns.2009.11.011 10.1136/gutjnl-2011-300486 10.1111/j.1572-0241.2002.05872.x 10.1111/j.1572-0241.2001.04683.x 10.1111/j.1365-2036.2008.03688.x 10.1053/j.gastro.2007.05.051 10.1136/gut.2007.138248 |
ContentType | Journal Article |
Copyright | Copyright © 2014 Crohn's & Colitis Foundation of America, Inc. 2014 Copyright © 2014 Crohn's & Colitis Foundation of America, Inc. |
Copyright_xml | – notice: Copyright © 2014 Crohn's & Colitis Foundation of America, Inc. 2014 – notice: Copyright © 2014 Crohn's & Colitis Foundation of America, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7T5 H94 |
DOI | 10.1097/MIB.0000000000000199 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1536-4844 |
EndPage | 2285 |
ExternalDocumentID | 25248002 10_1097_MIB_0000000000000199 10.1097/MIB.0000000000000199 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .Z2 0R~ 1OC 3WU 48X 53G 5GY 5VS 5WD 66C 7O~ 8-0 8UM AAAXR AABZA AACZT AAKAS AAPQZ AAPXW AARHZ AARTV AAUAY AAVAP AAYEP ABBUW ABDFA ABEJV ABGNP ABJNI ABNHQ ABOCM ABPQP ABPTD ABQNK ABVGC ABWST ABXVJ ABXVV ABZAD ACDDN ACEWG ACGFO ACGFS ACUTJ ACWDW ACWRI ACXNZ ACYHN ADBBV ADBIZ ADGZP ADIPN ADQBN ADRTK ADVEK ADZCM AENEX AETBJ AFFZL AFOFC AFTRI AFUWQ AFXAL AGINJ AGQXC AGUTN AHMBA AHMMS AIJEX AIZYK AJEEA ALMA_UNASSIGNED_HOLDINGS ATGXG AWKKM BAYMD BCRHZ BEYMZ BOYCO BTRTY C45 CDBKE CS3 DAKXR DR2 DU5 E.X E3Z EBS EJD ENERS EX3 F5P FECEO FL- FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H0~ HZ~ IN~ IX1 KBUDW KOP KSI KSN LAW MHKGH NNB NOMLY NOYVH NVLIB N~7 N~B O9- OAUYM OCZFY ODMLO OIG OJZSN OPAEJ OVD OWPYF P2P PAFKI PQQKQ QRW ROX RUSNO RX1 S4S TEORI V2E WOW XV2 YAYTL YKOAZ YXANX ZFV 31~ 4.4 7X7 8-1 88E 8F7 8FI 8FJ AAJQQ AAPGJ AAUQX AAWDT AAYXX ABUWG ACFRR ACVCV ACXQS ACZBC ADMTO ADNBA AEMQT AFBPY AFFQV AFKRA AFYAG AFZJQ AGKRT AGMDO AHGBF AHRYX AJAOE AJBYB AJDVS AJNCP AJNYG ALXQX APJGH AQDSO AQKUS AVNTJ BENPR CCPQU CITATION EIHJH FYUFA H13 HMCUK IAO IHR ITC JXSIZ LH4 LW6 M1P MBLQV NU- OBFPC OCUKA ORVUJ PHGZM PHGZT PJZUB PPXIY PSQYO PUEGO ROL TMA UKHRP W99 WOQ Y6R CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AGORE K9. PKEHL PQEST PQUKI PRINS 7X8 7T5 H94 |
ID | FETCH-LOGICAL-c408t-7e896315e187549a77f2275fc6521f9f258e3d7fc711c9fccbd09592ca2f63513 |
IEDL.DBID | 7X7 |
ISSN | 1078-0998 1536-4844 |
IngestDate | Sun Sep 28 00:10:39 EDT 2025 Sun Sep 28 08:34:10 EDT 2025 Fri Sep 19 20:52:59 EDT 2025 Wed Feb 19 02:41:17 EST 2025 Wed Oct 01 04:56:46 EDT 2025 Thu Apr 24 23:07:04 EDT 2025 Sat Feb 08 08:13:08 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | mesalazine ulcerative colitis multimatrix system inflammatory bowel disease web-based management |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c408t-7e896315e187549a77f2275fc6521f9f258e3d7fc711c9fccbd09592ca2f63513 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 25248002 |
PQID | 3169799922 |
PQPubID | 996336 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1680456939 proquest_miscellaneous_1625344140 proquest_journals_3169799922 pubmed_primary_25248002 crossref_citationtrail_10_1097_MIB_0000000000000199 crossref_primary_10_1097_MIB_0000000000000199 oup_primary_10_1097_MIB_0000000000000199 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20141201 2014-12-00 2014-Dec |
PublicationDateYYYYMMDD | 2014-12-01 |
PublicationDate_xml | – month: 12 year: 2014 text: 20141201 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: England – name: Baltimore |
PublicationTitle | Inflammatory bowel diseases |
PublicationTitleAlternate | Inflamm Bowel Dis |
PublicationYear | 2014 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Walmsley (R37-9-20141113) 1998; 43 Baars (R14-9-20141113) 2009; 30 Inokuchi (R58-9-20141113) 2014; 20 Langholz (R3-9-20141113) 1996; 31 (R48-9-20141113) 2010; 24 Shale (R31-9-20141113) 2003; 18 Higgins (R24-9-20141113) 2009; 29 Lopez San (R19-9-20141113) 2005; 97 Travis (R56-9-20141113) 2012; 61 Burisch (R43-9-20141113) 2014; 8 Burisch (R2-9-20141113) 2014; 20 Ford (R8-9-20141113) 2011; 106 Kamm (R26-9-20141113) 2008; 57 Kane (R9-9-20141113) 2011; 56 Ford (R7-9-20141113) 2011; 106 Ohm (R41-9-20141113) 2006; 38 Langholz (R1-9-20141113) 1999; 46 Lakatos (R18-9-20141113) 2010; 4 Kane (R49-9-20141113) 2012; 18 Lichtenstein (R6-9-20141113) 2011; 33 Munkholm (R10-9-20141113) 2010; 22 Jowett (R36-9-20141113) 2003; 38 Kane (R11-9-20141113) 2006; 23 Travis (R32-9-20141113) 2008; 2 Elkjaer (R34-9-20141113) 2010; 22 Ediger (R16-9-20141113) 2007; 102 Sewitch (R22-9-20141113) 2003; 98 Schoepfer (R52-9-20141113) 2009; 15 Irvine (R42-9-20141113) 1996; 91 Dignass (R46-9-20141113) 2009; 7 Marteau (R5-9-20141113) 2005; 54 Talley (R47-9-20141113) 2011; 106 Elkjaer (R12-9-20141113) 2010; 59 Hunot (R40-9-20141113) 2007; 9 Elkjaer (R38-9-20141113) 2010; 31 Higgins (R35-9-20141113) 2005; 54 Kamm (R25-9-20141113) 2007; 132 De (R51-9-20141113) 2012; 6 Kane (R23-9-20141113) 2002; 97 Burisch (R44-9-20141113) 2014; 61 Schoepfer (R53-9-20141113) 2012; 6 Pedersen (R33-9-20141113) 2012; 36 Lichtenstein (R29-9-20141113) 2008; 27 Kane (R13-9-20141113) 2001; 96 Gifford (R17-9-20141113) 2013; 108 Long (R21-9-20141113) 2012; 18 Solomon (R54-9-20141113) 2012; 35 Yi (R57-9-20141113) 2013; 10 Lichtenstein (R28-9-20141113) 2007; 5 DHaens (R50-9-20141113) 2012; 18 Delvincourt (R59-9-20141113) 2014; 39 Horne (R39-9-20141113) 2013; 8 Moshkovska (R20-9-20141113) 2011; 17 Schreiber (R30-9-20141113) 2008; 2 Froslie (R55-9-20141113) 2007; 133 Kamm (R27-9-20141113) 2009; 15 Ware (R45-9-20141113) 1998; 51 Cerveny (R15-9-20141113) 2007; 13 26111214 - Inflamm Bowel Dis. 2015 Aug;21(8):E15-6 26083615 - Inflamm Bowel Dis. 2015 Aug;21(8):E14-5 |
References_xml | – volume: 6 start-page: 412 year: 2012 ident: R53-9-20141113 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2011.09.008 – volume: 18 start-page: 1026 year: 2012 ident: R49-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.21841 – volume: 35 start-page: 1386 year: 2012 ident: R54-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2012.05107.x – volume: 59 start-page: 1652 year: 2010 ident: R12-9-20141113 publication-title: Gut doi: 10.1136/gut.2010.220160 – volume: 2 start-page: 24 year: 2008 ident: R32-9-20141113 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2007.11.002 – volume: 5 start-page: 95 year: 2007 ident: R28-9-20141113 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2006.10.025 – volume: 18 start-page: 191 year: 2003 ident: R31-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.2003.01648.x – volume: 43 start-page: 29 year: 1998 ident: R37-9-20141113 publication-title: Gut doi: 10.1136/gut.43.1.29 – volume: 18 start-page: 2099 year: 2012 ident: R21-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.22895 – volume: 132 start-page: 66 year: 2007 ident: R25-9-20141113 publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.10.011 – volume: 102 start-page: 1417 year: 2007 ident: R16-9-20141113 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2007.01212.x – volume: 31 start-page: 323 year: 2010 ident: R38-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2009.04164.x – volume: 20 start-page: 509 year: 2014 ident: R58-9-20141113 publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i2.509 – volume: 38 start-page: 164 year: 2003 ident: R36-9-20141113 publication-title: Scand J Gastroenterol doi: 10.1080/00365520310000654 – volume: 13 start-page: 1244 year: 2007 ident: R15-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20189 – volume: 9 start-page: 91 year: 2007 ident: R40-9-20141113 publication-title: Prim Care Companion J Clin Psychiatry doi: 10.4088/PCC.v09n0202 – volume: 51 start-page: 1167 year: 1998 ident: R45-9-20141113 publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(98)00108-5 – volume: 108 start-page: 249 year: 2013 ident: R17-9-20141113 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2012.419 – volume: 91 start-page: 1571 year: 1996 ident: R42-9-20141113 publication-title: Am J Gastroenterol – volume: 106 start-page: S2 year: 2011 ident: R47-9-20141113 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.58 – volume: 7 start-page: 762 year: 2009 ident: R46-9-20141113 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.04.004 – volume: 30 start-page: 864 year: 2009 ident: R14-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2009.04103.x – volume: 106 start-page: 601 year: 2011 ident: R8-9-20141113 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.67 – volume: 10 start-page: 43 year: 2013 ident: R57-9-20141113 publication-title: Virol J doi: 10.1186/1743-422X-10-43 – volume: 54 start-page: 782 year: 2005 ident: R35-9-20141113 publication-title: Gut doi: 10.1136/gut.2004.056358 – volume: 54 start-page: 960 year: 2005 ident: R5-9-20141113 publication-title: Gut doi: 10.1136/gut.2004.060103 – volume: 106 start-page: 2070 year: 2011 ident: R7-9-20141113 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.296 – volume: 8 start-page: e80633 year: 2013 ident: R39-9-20141113 publication-title: PLoS One doi: 10.1371/journal.pone.0080633 – volume: 22 start-page: 695 year: 2010 ident: R34-9-20141113 publication-title: Eur J Gastroenterol Hepatol – volume: 38 start-page: 292 year: 2006 ident: R41-9-20141113 publication-title: J Nurs Scholarsh doi: 10.1111/j.1547-5069.2006.00116.x – volume: 61 start-page: B4778 year: 2014 ident: R44-9-20141113 – volume: 15 start-page: 1851 year: 2009 ident: R52-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20986 – volume: 23 start-page: 577 year: 2006 ident: R11-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2006.02809.x – volume: 31 start-page: 260 year: 1996 ident: R3-9-20141113 publication-title: Scand J Gastroenterol doi: 10.3109/00365529609004876 – volume: 36 start-page: 840 year: 2012 ident: R33-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12043 – volume: 18 start-page: 2218 year: 2012 ident: R50-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.22917 – volume: 15 start-page: 1 year: 2009 ident: R27-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20580 – volume: 2 start-page: 299 year: 2008 ident: R30-9-20141113 publication-title: Expert Rev Gastroenterol Hepatol doi: 10.1586/17474124.2.3.299 – volume: 22 start-page: 912 year: 2010 ident: R10-9-20141113 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32833944bf – volume: 97 start-page: 249 year: 2005 ident: R19-9-20141113 publication-title: Rev Esp Enferm Dig – volume: 98 start-page: 1535 year: 2003 ident: R22-9-20141113 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2003.07522.x – volume: 24 start-page: 127 year: 2010 ident: R48-9-20141113 publication-title: Mesalazine in inflammatory bowel disease: a trendy topic once again Can J Gastroenterol – volume: 6 start-page: 557 year: 2012 ident: R51-9-20141113 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2011.11.002 – volume: 33 start-page: 672 year: 2011 ident: R6-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2010.04575.x – volume: 17 start-page: 1874 year: 2011 ident: R20-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.21570 – volume: 56 start-page: 3463 year: 2011 ident: R9-9-20141113 publication-title: Dig Dis Sci doi: 10.1007/s10620-011-1877-6 – volume: 8 start-page: 1030 year: 2014 ident: R43-9-20141113 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2014.01.028 – volume: 39 start-page: 712 year: 2014 ident: R59-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12650 – volume: 29 start-page: 247 year: 2009 ident: R24-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2008.03865.x – volume: 20 start-page: 36 year: 2014 ident: R2-9-20141113 publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000436277.13917.c4 – volume: 4 start-page: 283 year: 2010 ident: R18-9-20141113 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2009.11.011 – volume: 61 start-page: 535 year: 2012 ident: R56-9-20141113 publication-title: Gut doi: 10.1136/gutjnl-2011-300486 – volume: 97 start-page: 1853 year: 2002 ident: R23-9-20141113 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2002.05872.x – volume: 96 start-page: 2929 year: 2001 ident: R13-9-20141113 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2001.04683.x – volume: 27 start-page: 1094 year: 2008 ident: R29-9-20141113 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2008.03688.x – volume: 133 start-page: 412 year: 2007 ident: R55-9-20141113 publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.05.051 – volume: 46 start-page: 400 year: 1999 ident: R1-9-20141113 publication-title: Dan Med Bull – volume: 57 start-page: 893 year: 2008 ident: R26-9-20141113 publication-title: Gut doi: 10.1136/gut.2007.138248 – reference: 26083615 - Inflamm Bowel Dis. 2015 Aug;21(8):E14-5 – reference: 26111214 - Inflamm Bowel Dis. 2015 Aug;21(8):E15-6 |
SSID | ssj0020209 |
Score | 2.4030962 |
Snippet | To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease... BackgroundTo individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term... Background: To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term... |
SourceID | proquest pubmed crossref oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2276 |
SubjectTerms | Adult Aged Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Colitis, Ulcerative - drug therapy Colitis, Ulcerative - psychology Computer-Assisted Instruction Drug Administration Schedule Female Follow-Up Studies Health Knowledge, Attitudes, Practice Humans Inflammatory bowel disease Internet Male Medication Adherence Mesalamine - therapeutic use Middle Aged Patient Education as Topic Precision Medicine Prognosis Prospective Studies Quality of Life Recurrence Self Care Severity of Illness Index Telemedicine Young Adult |
Title | eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25248002 https://www.proquest.com/docview/3169799922 https://www.proquest.com/docview/1625344140 https://www.proquest.com/docview/1680456939 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1536-4844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020209 issn: 1078-0998 databaseCode: 7X7 dateStart: 19960201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1536-4844 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020209 issn: 1078-0998 databaseCode: BENPR dateStart: 19960201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1078-0998 databaseCode: DR2 dateStart: 19950101 customDbUrl: isFulltext: true eissn: 1536-4844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020209 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS-QwFA6rwuKL6O6q440s7MO-BJs0aRpfxCu6UBF3hp230kkTGCit2vEX-Mc9adIZdEHtW-lpG3pOer5zR-iXBpshSiJFEiYN4SbhpAALjETCKG0NE2XX7Dm7Sa5G_M9YjIPDrQ1plf0_sftRl412PvLDmCYuAqUYO75_IG5qlIuuhhEaS2iFAlRxUi3HC4Mr8ikeYOG4EL9K-9I5JQ-z61PfurA_fPfXhWp6Ve72H-rstM_lOloLsBGfeD5voC-m_oa-ZiEw_h09G19PdISv5xVWocISNxZnpi2qrpE0HvaZ5XjoR_TgAv81lSU-j7XE_8yEON1W4t5lhqc1zqZVSWYNcZNzXHcJPKq08V3D8VmXQ9f-QKPLi-HZFQnzFQhwKJ0RaVLYflQYCkYLV4WUljEprE5Ap1tlmUhNXEqrJaVaWa0npfMaMl0wCziFxptouW5qs42wVFayGIgiG3N4SDGhqRZJKhLLhWBigOL-0-Y6NB93MzCqvA-CA0PytwwZIDK_69433_iA_jdw7ZOkez1r87Br23whYwP0c34Z9psLohS1aZ7anILBGAOG5NF7NKlDyiqG12x5sZkvignGHUjfeX8Bu2gVoBn3iTN7aHn2-GT2Af7MJgedjB-gldOLm9s7ODu_Yy_0EvzR |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9QwDLfGkIAXxH8OBgQJJF6itWnSNEgIwWC6Y-teuBP3VnppIk2q2m29adoz32efcU7T3AmQBi_ra900ip3Yju2fAd5o9BmiNFI0ZdJQblJOS_TAaCSM0tYwUfVgz_lBOp7xb3Mx34CLUAvj0irDmdgf1FWr3R35dhKnLgKlGPt4dExd1ygXXQ0tNLxY7JnzM3TZug-TL8jft4ztfp3ujOnQVYDivLIllSZDoYuFidFU56qU0jImhdUpajKrLBOZSSpptYxjrazWi8rdlTFdMovaOU5w3BtwkycRd1j9cr528CKfUoIelUspUFko1VNyO5989lCJ4fFos2tV-Ft53V9Wbq_tdu_B3cFMJZ-8XN2HDdM8gFv5EIh_CL-Mr196Tyariq6hopO0luSmK-seuJpMQyY7mfqWQKQk301tqc-brcgPs6BOl1YkXNGRw4bkh3VFly11nXocmgWZ1dp4lHKy0-fsdY9gdi0r_xg2m7YxT4FIZSVLkCiyCcdBykWcaZFmIrVcCCZGkISlLfQAdu56btRFCLojQ4o_GTICuvrqyIN9_IP-HXLtP0m3AmuL4ZToirVMj-D16jXubxe0KRvTnnZFjA5qgjYrj66iyZxlrhL8zRMvNqtJMcG4cwqeXT2BV3B7PM33i_3Jwd5zuINmIfdJO1uwuTw5NS_Q9FouXvbyTuDndW-wS9U4Nik |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=eHealth&rft.jtitle=Inflammatory+bowel+diseases&rft.au=Pedersen%2C+Natalia&rft.au=Thielsen%2C+Peter&rft.au=Martinsen%2C+Lars&rft.au=Bennedsen%2C+Mette&rft.date=2014-12-01&rft.issn=1078-0998&rft.volume=20&rft.issue=12&rft.spage=2276&rft.epage=2285&rft_id=info:doi/10.1097%2FMIB.0000000000000199&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_MIB_0000000000000199 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0998&client=summon |